Galiximab in Treating Patients With Relapsed or Refractory Hodgkin’s Lymphoma
Study Information
Alliance Study ID: CALGB-50602
NCT Study ID (ClinicalTrials.gov): NCT00516217
Alliance Committee: Lymphoma
Disease or Cancer Type: Lymphoma
Alliance Study Chair: Sonali Smith, MD
Status: COMPLETED
Study Description
RATIONALE: Monoclonal antibodies, such as galiximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them.
PURPOSE: This phase II trial is studying how well galiximab works in treating patients with relapsed or refractory Hodgkin’s lymphoma.
Related Publications
For publications related to this and other clinical trials, visit the Alliance Publications Application.
Data Sources & Contacts
Full trial details
For more Information